Why The Launch Of ‘Hogwarts Legacy’ On Nintendo Switch Has Been Delayed

The launch of Warner Bros.

The launch of Warner Bros. Discovery‘s (NASDAQ:WBD) “Hogwarts Legacy” on Nintendo Co., Ltd.‘s (OTC:NTDOY) Nintendo Switch has been delayed to ensure further optimization.

The game, which came out in February for PlayStation 5 (PS5), Xbox Series X and S, and PC players, has sold 256% more than predicted, earning more than $850 million with more than 12 million units sold in its first two weeks.

See Also: Hogwarts Legacy Shatters Records As The Most Sold Harry Potter Game of All Time

Avalanche Software, a division of Warner Bros. Games and developer of the title that was set to release in July, took to Twitter to announce the delay and the new date of launch.

“Hogwarts Legacy launches on Nintendo Switch on 11/14/23. We know fans are looking forward to playing on Switch, therefore creating the best possible experience is our top priority. Thank you for your patience,” Avalanche Software wrote.

The reason behind this hold-up is that the Nintendo Switch lags behind in terms of processing capabilities, even when compared to the standard PlayStation 4. This has led to the cancellation of Switch ports for titles like “Marvel’s Midnight Suns,” as studios have admitted defeat on the platform.

Read Next: ‘Marvel’s Midnight Suns’ No Longer Coming To Nintendo Switch: Here’s Where You Can Play

Image credits: Riccio da favola on Shutterstock and logo on Wikipedia

Total
0
Shares
Related Posts
Read More

US Commerce Department Grants $75M To Absolics For Semiconductor Facility In Georgia

The U.S. Commerce Department has awarded Absolics Inc a $75 million grant to build a 120,000 square-foot facility in Covington, Georgia, under the CHIPS and Science Act. This investment will boost U.S. semiconductor technology by advancing glass substrate technology for semiconductor packaging. Expected to create 1,200 jobs, this initiative supports the $52.7 billion government effort to enhance semiconductor manufacturing and development.

AMAT

Read More

BioVie Announces Topline Results From Investigator-Sponsored Exploratory Biomarker And Imaging Trial Of NE3107 For Treatment Of Alzheimer’s Disease; Says ‘Vast majority of patients saw significant improvements in the Global Rating of Change’

Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient's daily abilities) with NE3107 treatment (p<0.0001 to p<0.05).   NE3107 is

BIVI